ALKtALK Season 7 premieres Sunday, Sept. 27 at 7 p.m. ET with Dr. Eric Singhi (@lungoncdoc) of MD Anderson. Join us on Zoom for WCLC updates, practical information for life with ALK-positive cancer, and live Q&A.
@alkpositive.bsky.social
@alkpositive.bsky.socialALKtALK Season 7 premieres Sunday, Sept. 27 at 7 p.m. ET with Dr. Eric Singhi (@lungoncdoc) of MD Anderson. Join us on Zoom for WCLC updates, practical information for life with ALK-positive cancer, and live Q&A.
@alkpositiveuk.bsky.socialCould alectinib be used before surgery for ALK+ #lungcancer?
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
@alkpositiveuk.bsky.socialScotland has confirmed routine NHS access to lorlatinib after previous ALK+ lung cancer treatment.
It had been available on an interim basis since 2020. Following reassessment and further evidence, that access is now routine.
@alkpositiveuk.bsky.socialNew research is helping us understand why ALK targeted treatments can stop working.
In 148 people with ALK+ #lungcancer, researchers identified changes in the RAS pathway as one possible route of resistance.
An important clue for future research.